Background and Purpose-Peripheral immune cell infiltration contributes to neural injury after ischemic stroke. However, in contrast to lymphocytes and neutrophils, the role of different monocyte/macrophage subsets remains to be clarified. Therefore, we evaluated the effects of selective and unselective monocyte/macrophage depletion and proinflammatory (M1-) and anti-inflammatory (M2-) macrophage transfer on the outcome after experimental cerebral ischemia. Methods-To assess short-term effects of monocytes/macrophages in acute ischemic stroke, mice underwent transient middle cerebral artery occlusion and received either clodronate liposomes for unselective macrophage depletion, MC-21-antibody for selective depletion of proinflammatory Ly-6C high monocytes, or proinflammatory (M1-) or anti-inflammatory (M2-) macrophage transfer. In addition, the impact of MC-21-antibody administration and M2-macrophage transfer on long-term neural recovery was investigated after photothrombotic stroke. Neurobehavioral tests were used to analyze functional outcomes, infarct volumes were determined, and immunohistochemical analyses were performed to characterize the postischemic inflammatory reaction. Results-Selective and unselective monocyte/macrophage depletion and M1-and M2-macrophage transfer did not influence tissue damage and neurobehavioral outcomes in the acute phase after middle cerebral artery occlusion. Beyond, selective depletion of Ly-6C high monocytes and M2-macrophage transfer did not have an impact on neural recovery after photothrombotic stroke. Conclusions-Targeting different monocyte/macrophage subsets has no impact on outcome after ischemic stroke in mice.
P ostischemic immune cell immigration is a major determinant of stroke outcome. 1, 2 Among immigrating immune cells, neutrophils and macrophages were identified as the most numerous invading cell populations, followed by myeloid dendritic cells and lymphocytes. 3 Over the past years, several studies have investigated the functional relevance of lymphocytes and neutrophils in stroke pathophysiology, uncovering predominantly harmful features of lymphocytes and neutrophils. [4] [5] [6] In contrast to lymphocytes and neutrophils, the functional relevance of different monocyte/macrophage subsets after ischemic stroke has been scarcely investigated, even though the number of infiltrating monocytes/macrophages exceeds the number of infiltrating lymphocytes by far. 3 A previous study showed that monocytes/macrophages may prevent hemorrhagic infarct transformation, but the overall contribution of monocytes/macrophages on stroke outcome is still unclear. 7 Targeting monocytes and monocytederived macrophages might be of particular interest, although, because recent studies in different disease models have identified distinct subsets of monocytes and monocyte-derived macrophages with opposing characteristics. 8, 9 On the one hand, proinflammatory monocytes expressing high levels of Ly-6C antigen and C-C chemokine receptor 2 (CCR2) are recruited to sites of acute inflammation via CCR2, release proinflammatory cytokines like interleukin (IL)-1β, IL-6, and tumor necrosis factor-α, and promote necrotic cell clearance. [9] [10] [11] On the other hand, monocytes with low Ly-6C-expression are recruited via fractalkine receptor CX3CR1 and release antiinflammatory mediators such as transforming growth factor-β, IL-10, and VEGFα (vascular endothelial growth factor α), thus limiting inflammation and enhancing neoangiogenesis and tissue repair. [9] [10] [11] Accordingly, monocyte-derived macrophages
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are classified into classically activated, proinflammatory (M1-) macrophages, which augment parenchymal inflammation, and alternatively activated, anti-inflammatory (M2-) macrophages, which promote structural regeneration. 8, 12 After different tissue injuries, these monocyte/macrophage subsets are sequentially activated and orchestrate the early inflammatory response and subsequent structural remodeling and repair. 9, 10 For instance, selective targeting of monocyte/macrophage subsets in models of spinal cord injury and myocardial infarction has demonstrated that the intravenous delivery of bone marrow-derived M2-polarized macrophages may enhance structural repair and functional recovery, whereas monocyte and macrophage depletion impedes healing and regeneration. 8, 13, 14 But, in spite of the huge number of infiltrating monocytes/ macrophages and broadly acknowledged prognostic importance of the inflammatory reaction after stroke, only few studies have investigated the functional relevance of distinct monocyte/macrophage subsets in acute ischemic stroke, [15] [16] [17] whereas long-term effects of monocytes/macrophages on neural recovery beyond the acute phase have not been investigated at all. Therefore, we aimed to elaborate short-term and long-term effects of distinct monocyte/macrophage subpopulations in 2 animal models of ischemic stroke.
Materials and Methods
A detailed description of experimental procedures is provided in the online-only Data Supplement. All experiments were performed in a fully randomized and blinded design.
First, to investigate the pathophysiological role of different monocyte subsets in the acute phase of ischemic stroke, we analyzed the effects of an unselective macrophage depletion by daily administration of clodronate liposomes (200 µL/d IP, 5 mg clodronate/mL) and intravenous transplantation of either 2 million proinflammatory M1-or anti-inflammatory M2-macrophages on functional and histological outcomes 6 days after middle cerebral artery occlusion (MCAO; Figure 1A ). To induce a proinflammatory M1-macrophage polarization, bone marrow-derived macrophages were stimulated with 5 ng/mL interferon-γ (eBioscience, San Diego, CA) for 48 hours before harvest, as described previously. 18, 19 To induce an antiinflammatory M2-macrophage polarization, bone marrow-derived macrophages were treated with 10 ng/mL IL-4 (eBioscience) for 48 hours before harvest, as described previously. 18, 19 To verify our protocols of macrophage polarization, we determined markers associated with M1 and M2 polarization in the supernatant by griess assay, ELISA, and real-time polymerase chain reaction. Successful macrophage depletion was verified by flow cytometry of peripheral blood samples 24 and 72 h after MCAO. For functional outcome assessment, we used a modification of Menzies neuroscore, which ranges from 0 (no deficit) to 5 (death), 20 and the rotarod test as described previously. 21 Second, we investigated the effects of selective depletion of proinflammatory Ly6C high -monocytes on functional and histological outcomes 6 days after MCAO. For selective depletion of Ly-6C high monocytes, animals received daily intraperitoneal injections of 20 µg MC-21-antibody against the CCR2, which is homogeneously expressed on monocytes. 22 IgG-isotype-antibody-treated animals (rat IgG2b, low endotoxin, azide-free; BioLegend, San Diego, CA) served as additional control group ( Figure 1B ). Successful monocyte depletion was verified by flow cytometry of peripheral blood samples 24 and 72 h after MCAO.
In addition, we investigated the effects of MC-21-antibody treatment and M2-macrophage transplantation on neural recovery beyond the acute phase after photothrombotic stroke ( Figure 1C ). MC-21-antibody treatment was initiated 1 hour before ischemia and continued once daily for 5 days. M2-macrophages were administered before photothrombosis and thereafter three times per week for 2 weeks. For functional outcome assessment, we used the adhesive tape removal test and foot fault test, as described previously. 23, 24 Detailed descriptions of functional tests, infarct volume assessment, and immunohistochemical analyses are provided in the online-only Data Supplement.
Results
Unselective Macrophage Depletion Increases Mortality, but Does Not Affect Neurological Outcomes in Acute Stroke
Because hematogenous macrophages infiltrate ischemic lesions in huge numbers and potentiate the postischemic inflammation, 3 we aimed to investigate whether macrophage depletion improved functional and structural outcomes after stroke. Surprisingly, depletion of hematogenous macrophages by clodronate liposomes did not improve outcomes 6 days after MCAO, but even increased mortality (Figure 2A ; logrank (Mantel-Cox) test, P=0.001). Neuroscores, rotarod performances, and infarct volumes of surviving mice were not significantly affected (repeated-measures ANOVA, P=0.65 and P=0.93 and 1-way ANOVA, P=0.7; Figure 2A ). We did not observe hemorrhagic infarct transformation, as it was reported previously. 7 Successful macrophage depletion was verified by flow cytometry analyses of peripheral blood samples ( Figure 2B ). As the increased mortality 6 days after macrophage depletion might have been attributable to particularly large infarct volumes among deceased mice, we analyzed neuroscores and infarct volumes 24 and 72 hours after MCAO and macrophage depletion. However, neuroscores and infarct volumes did not differ 24 hours after MCAO and macrophage depletion (t test, P=0.11 and P=0.58; Figure 2C ), and neuroscores and infarct volumes did not differ 72 hours after MCAO and macrophage depletion, either (repeated-measures ANOVA and t test, P=0.91 and P=0.53; Figure 2C ). The observed increase in mortality might thus also be related to toxicity and systemic effects of clodronate liposomes. 25 Apart from macrophage depletion, we moreover investigated the effects of an opposing approach and transferred either proinflammatory M1-or anti-inflammatory M2-macrophages. But, as shown by Figure 2 , the transfer of either proinflammatory M1-or anti-inflammatory M2-macrophages did not have an impact on neuroscores or rotarod performances (repeated-measures ANOVA, P=0.65 and P=0.93) and infarct volumes did not differ, either (one-way ANOVA, P=0.75). Because these neutral results could be because of the fact that transferred macrophages did not immigrate into brain parenchyma, we used GFP-transgenic mice (C57BL6/-green fluorescent protein [GFP]) as bone marrow donors and performed immunohistochemical analyses to verify a successful macrophage transfer. As illustrated by Figure 3A , GFP-expressing macrophages could be identified in the periinfarct area, thus demonstrating successful macrophage transfer. Further immunohistochemical analyses did not reveal differences in the density of ipsilateral astrogliosis, the number of microglial cells in the infarct area, and the number of granulocytes in the infarct area ( 
Selective Depletion of Proinflammatory Monocytes Does Not Affect Outcomes in Acute Stroke
Because the combined depletion of proinflammatory M1-and anti-inflammatory M2-macrophages did not improve outcomes, and the observed increase in mortality might be because of systemic toxicity of clodronate liposomes, we changed our approach and investigated the consequences of an antibody-mediated, selective depletion of proinflammatory Ly6C high -monocytes using MC-21-antibody, which is well tolerated and does not induce systemic toxicity. 22 Successful depletion of Ly6C high -monocytes subsequent to MC-21-antibody administration was verified by flow cytometry analyses of peripheral blood samples ( Figure 4A ). In contrast to clodronate liposomes, MC-21-administration did not influence mortality after MCAO (log-rank (Mantel-Cox) test, P=0.23; Figure 4B ). However, selective depletion of proinflammatory monocytes did not affect neuroscores, rotarod performances, and infarct volumes, either (repeated-measures ANOVA, P=0.62 and P=0.98 and 1-way ANOVA, P=0.24; Figure 4B ). Immunohistochemical analyses did not reveal differences in the density of ipsilateral astrogliosis, the number of microglial cells in the infarct area, and the number of granulocytes in the infarct area (1-way ANOVA, P=0.10, P=0.83, and P=0.84; Figure 4C ).
Polarization of Resident Microglia and Immigrated Macrophages Is Not Influenced by Macrophage Transfer and Monocyte/Macrophage Depletion
As both, macrophage transfer as well as selective and unselective depletion of circulating monocytes/macrophages, did not influence functional outcomes and infarct sizes, we aimed to exclude that missing treatment effects were related to an altered polarization of brain resident and immigrated immune cells. Therefore, we chose the exemplary M1-marker CD16/32 8, 26 and the exemplary M2-marker Arginase-1 8, 27 and evaluated cell counts and distribution pattern by immunofluorescence after M1-and M2-macrophage transfer and monocyte/macrophage depletion in 5 animals per group. Immunohistochemical double staining of CD16/32 with microglia-/macrophage-specific IBA-1 (ionized calciumbinding adapter protein-1) showed a constant colocalization indicating an almost sole expression of CD16/32 by resident and immigrated microglia and macrophages ( Figure 5A ). Arginase-1-immunostaining showed a pronounced cellular fluorescence signal limited to the infarct area. Double-staining analysis revealed that the vast majority of Arginase-1 + cells were also positive for microglia/macrophage marker F4/80 ( Figure 5B ). Arginase-1 + /F4/80 -cells were mostly seen in close vicinity to blood vessels with a clumsy shape and moderate ramification. After M1-and M2-macrophage transfer and clodronate-mediated macrophage depletion, neither the number of CD16/32 + cells nor the number of Arginase-1 + cells showed significant differences between treatment groups 6 days after MCAO (1-way ANOVA, P=0.18 and P=0.17; Figure 5C ). Evaluation of the distribution pattern showed CD16/32 + and Arginase-1 + cells particularly within the infarct area and periinfarct area of all investigated groups. MC-21-antibody treatment did not influence the number of CD16/32 + and Arginase-1 + cells 6 days after reperfusion when compared with the control group ( Figure 5D ). And saturation plots for CD16/32 and Arginase-1 did not show any differences between treatment groups, either (1-way ANOVA, P=0.95 and P=0.50).
Monocytes Are Not Relevant for Neural Recovery After Ischemic Stroke
Although we found no effect in the acute phase after stroke, macrophages might still influence long-term neural recovery after stroke. To analyze recovery, we used a model of photothrombotic stroke, which is characterized by long-term sensorimotor deficits and low mortality. 28 As illustrated by the adhesive tape removal and foot fault tests, selective depletion of proinflammatory monocytes did not have an impact on the sensorimotor recovery (repeated-measures ANOVA, P=0.24 and P=0.54; Figure 6 ). Moreover, infarct volumes did not differ 6 weeks after photothrombotic stroke (1-way ANOVA, P=0.53; Figure 6 ).
Because the macrophage response after stroke comprises an interplay of proinflammatory and anti-inflammatory monocyte/macrophage subsets, we moreover investigated the effects of an opposing approach and transferred antiinflammatory M2-macrophages after photothrombotic stroke.
However, as shown by Figure 6 , the transfer of anti-inflammatory M2-macrophages influenced neither the sensorimotor recovery (repeated-measures ANOVA, P=0.24 and P=0.54) nor infarct volumes 6 weeks after photothrombotic stroke (1-way ANOVA, P=0.53).
Discussion
In our study, modulating the monocyte/macrophage response influenced neither short-term neurological outcomes in the acute phase of ischemic stroke nor neural recovery beyond the acute phase of stroke.
As clodronate liposomes increased mortality, but affect neither neurological outcomes of surviving animals nor any of the histological outcomes, we assume that increased mortality 
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April 2017 among clodronate-treated animals might be related to toxic effects of clodronate, which were described previously. 25 The failure to observe differences in neurological and histological outcomes after unselective macrophage depletion could be attributed to simultaneous depletion of both macrophage subsets, thus outbalancing potentially opposing effects of M1-and M2-macrophages. Because unselective macrophage depletion did not improve outcomes, and the observed increase in mortality might be because of systemic toxicity of clodronate liposomes, we applied another approach and investigated the consequences of an antibody-mediated, selective depletion of proinflammatory Ly6C high -monocytes using MC-21-antibody. 22 MC-21-antibody administration was well tolerated and resulted in an almost complete depletion of proinflammatory monocytes. However, selective depletion of proinflammatory monocytes did not affect neuroscores, rotarod performances, and infarct volumes in acute ischemic stroke. Lacking treatment effects of selective monocyte depletion might be explained by a considerably high plasticity of monocytes and macrophages, which allows changes in phenotypes in response to environmental stimuli. 10, [29] [30] [31] In our experiments, Ly-6C low monocytes, recruited via fractalkine receptor CX3CR1, might thus have partly compensated for the lack of CCR2-dependent Ly-6C high monocytes. Similarly, transplanted M2-macrophages might have locally transformed into M1-macrophages and vice versa. This hypothesis is supported by our immunohistochemical analysis of monocyte/ macrophage polarization, which did not show differences in the polarization of microglia and macrophages after either M1-and M2-macrophage transfer or selective and unselective depletion of circulating monocytes/macrophages. Beyond, activated microglia, which outnumber infiltrating hematogenous macrophages more than twice, 3 may compensate for the loss of hematogenous macrophages after monocyte/macrophage depletion. Despite differences in phagocytic activity and cytokine release, 32 hematogenous macrophages and microglia have several common features after stroke. Similar to hematogenous macrophages, activated microglia are able to adopt different phenotypes with distinct functions that partly correspond to M1/M2-phenotypes of macrophages. 29, 30, 33 After ischemic stroke, activated microglia may either produce proinflammatory cytokines, free radicals, and proteolytic enzymes, thus resembling hematogenous M1-macrophages, or release anti-inflammatory cytokines to resolve inflammation and restore homeostasis, which corresponds to M2-macrophage functions. 29, 30 In view of these similarities between microglia and hematogenous macrophages, we postulate that resident microglia compensate for the loss of hematogenous macrophages in our experiments. The predominance of activated microglia over immigrating monocytes and macrophages would also explain lacking treatment effects of selective Ly-6C high monocyte depletion and intravenous transplantation of either M1-or M2-macrophages.
Other studies on the effects of unselective macrophage depletion after stroke yielded conflicting results. Ma et al, 34 for instance, observed an improved neurological recovery after MCAO and unselective macrophage depletion using clodronate liposomes. Gliem et al, 7 by contrast, reported 
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hemorrhagic transformation and clinical deterioration after MCAO and administration of clodronate liposomes. Perego et al 35 treated CD11b-DTR transgenic mice, expressing the human diphtheria toxin receptor under the control of the CD11b promoter, with diphtheria to induce monocyte depletion and found increased infarct volumes 24 hours after MCAO. Differences between these studies and our study might be related to differences in ischemia duration and macrophage depletion regimes.
Previous studies using pharmacological antagonization of CCR2 or Ly-6C high monocyte-deficient CCR2 −/− mice in models of ischemic stroke have also yielded conflicting results. In accordance with our findings, some studies reported neutral results after Ly-6C high monocyte depletion in models of acute ischemic stroke. 15, 36 Others, by contrast, found either smaller infarct sizes or worse functional outcomes and larger infarct sizes subsequent to Ly-6C high monocyte depletion. 16, 37, 38 In accordance with our findings, a previous study did not detect differences in functional outcomes and infarct volumes after transplantation of M2-macrophages in an MCAO model of stroke. 17 In models of spinal cord injury and myocardial infarction, the intravenous delivery of bone marrow-derived M2-polarized macrophages enhanced structural repair and functional recovery, whereas monocyte and macrophage depletion impeded healing and regeneration. 6, 13, 14 Therefore, we expected that the macrophage response was likewise important for neural recovery after ischemic stroke. However, in our study, neither selective depletion of proinflammatory monocytes nor M2-macrophage transfer influenced the sensorimotor recovery 6 weeks after photothrombotic stroke.
An important clinical implication of our study is that the approaches we used to modulate the monocyte/macrophage response could not identify monocytes/macrophages as relevant therapeutic targets in ischemic stroke. To date, experimental stroke studies on monocytes/macrophages are not conclusive and should not be taken to clinical trials.
Our study has strengths and limitations. Treatments were initiated before ischemia, which is a limitation from a translational point of view but ensured that we did not miss a potential therapeutic time window. If our experiments had shown a treatment effect of any intervention, the time window could have been explored in additional experiments. Our neutral results can definitely not be attributed to failures in monocyte/macrophage depletion, as monocyte/macrophage depletion was verified by flow cytometry. MC-21 administration was restricted to 5 days to avoid the production of neutralizing antibodies, which might be a limitation of our long-term experiment. However, a 5-day administration of MC-21 was demonstrated to have long-term effects on neural recovery after central nervous system injury. 13 A clear strength of our study is the use of 2 different stroke models. Neural recovery was analyzed in a model of photothrombotic stroke, which is characterized by low mortality and long-term sensorimotor deficits, thus being well suited for the investigation of neural recovery. 28 Shortterm effects of monocyte/macrophage subsets were assessed after MCAO, the most frequently applied stroke model. However, the inflammatory reaction after MCAO is critically influenced by lesion size and reperfusion. 29, 30 In the present study, targeting different monocyte/macrophage subsets did not influence functional and histological outcomes after 30 minutes of transient MCAO, but we cannot exclude treatment effects in more severe stroke models.
Conclusions
In our study, targeting different monocyte/macrophage subsets did not affect functional and histological outcomes in 2 models of ischemic stroke. 
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